In short
Clinical trials are studying 68Ganota-Anti-Her2 Vhh1 in people with cancer that has spread to the brain. These trials look at whether the scan signal from this study drug can help compare HER2-positive and HER2-negative brain metastasis and measure tumor targeting. The main focus is on imaging performance, not treatment.
Key points
- Clinical trials of 68Ganota-Anti-Her2 Vhh1 are studying imaging uptake in cancer patients with brain metastasis. The available trial is a Phase 2 interventional study with 30 participants and is now completed. It compares tumor targeting in HER2-positive and HER2-negative patients. The main outcomes are visual scoring and Standard Uptake Values, which measure how strongly the lesions appear on imaging. The focus is on whether the scan signal can help identify brain metastasis lesions.
Trial overview
The available study of 68Ganota-Anti-Her2 Vhh1 was an interventional trial in cancer patients with brain metastasis. It was designed to compare the uptake of the study agent in brain metastasis lesions from HER2-positive and HER2-negative patients.
The trial was completed and enrolled 30 participants. It was listed as Phase 2.
Who was studied
The study focused on people with cancer that had spread to the brain, which is called brain metastasis. The trial summary says the comparison was between HER2-positive and HER2-negative patients, so the research included both groups.
This means the trial was not looking at a broad cancer population, but at a more specific group with brain lesions that could be seen on imaging.
What the trial measured
The main outcome was the tumor targeting potential in brain metastasis. This was checked in two ways: first by a doctor scoring the scan as positive or negative, and second by measuring Standard Uptake Values (SUV).
SUV is a number used in imaging to show how much of the tracer is seen in the lesion. In this trial, the physician who read the scans was unaware of HER2 status, which helps reduce bias in the assessment.
Study design and phase
This was an interventional study, which means participants received the study intervention and the researchers measured the results. The phase was Phase 2, a stage that usually examines performance in a defined patient group after earlier testing.
The intervention was listed as 68Ga-NOTA-anti-HER2 VHH1 given by intravenous administration at 185 MBq. The trial data do not provide other treatment details beyond this study administration.
Key trial result focus
The brief summary shows that the main goal was to compare uptake of 68GaNOTA-Anti-HER2 VHH1 in brain metastasis lesions from HER2-positive and HER2-negative patients. So the trial was focused on imaging performance, not on treating the cancer itself.
Because the assessment was based on scan appearance and SUV measurement, the study aimed to see whether the tracer could help show tumor lesions more clearly in the brain.
Patient terms explained
Interventional means the researchers gave a study product and then measured what happened. Completed means the trial has finished collecting the planned information.
HER2 status is a label used to separate cancers into HER2-positive and HER2-negative groups. In this study, that label was used to compare how the imaging signal looked in each group.